News Headlines

  1. Siegfried Expands Production Capacity For Ophthalmic Drugs In El Masnou 5/23/2025

    Siegfried, a leading global Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical industry, today announced a further expansion of its ophthalmic drug manufacturing site in El Masnou near Barcelona, Spain.

  2. CDMO Bora Biologics Announces Plans To Expand San Diego Manufacturing Facility 5/22/2025

    Bora Biologics, a leading contract development and manufacturing organization (CDMO) specializing in biologics manufacturing, announced a major expansion of its U.S. FDA-registered commercial manufacturing facility in San Diego. This expansion will add state-of-the-art upstream and downstream GMP processing capabilities to meet the increasing demand for 2000L scale single-use biologics manufacturing, solidifying Bora Biologics' position as a premier biologics CDMO.

  3. Codexis' Landmark Presentations At TIDES USA Highlight Reproducibility And Process Simplification Of The ECO Synthesis Platform For Manufacturing siRNA 5/22/2025

    Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, presented data at the TIDES USA annual meeting in San Diego, California.

  4. Lonza Launches Design2Optimize Platform To Streamline API Development 5/22/2025

    Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), announced today the launch of its new Design2Optimize platform to enhance process development and manufacturing of small molecule APIs.

  5. Porton Advanced Announces Collaboration With TongEYE To Accelerate Development Of iPSC-RPEC Transplantation Therapy 5/22/2025

    Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with TongEye Medical Technology (TongEYE), an innovator focusing on cell therapy drugs for ophthalmic diseases.

  6. Bio Usawa And Pacific Environmental Technologies Announce Landmark Partnership To Develop And Deploy Modular cGMP Biomanufacturing Units For Africa 5/22/2025

    Bio Usawa, Inc., a biopharmaceutical company based in San Francisco, Kigali, and Nairobi, committed to expanding access to life-saving biologics in Africa and underserved regions, today announced an agreement with Pacific Environmental Technologies, Inc., a global leader in cleanroom facility design and construction, to design, build, and deploy state-of-the-art, self-contained modular biomanufacturing units.

  7. BioHarvest Secures New CDMO Contract To Develop Plant-Based Fragrance Compound 5/21/2025

    BioHarvest Sciences Inc. (“BioHarvest” or the “Company”), a company pioneering its patented Botanical Synthesis technology platform, today announced that the Company’s Botanical Synthesis CDMO Services division has secured a new contract to develop a plant-based fragrance compound derived from a plant that is under significant threat due to over harvesting and habitat loss.

  8. Northway Biotech Enters Manufacturing Agreement With Kaida BioPharma For Lead Oncology Program KAD101 5/21/2025

    Northway Biotech, Inc. ("Northway Biotech"), an end-to-end biologics Contract Development and Manufacturing Organization (CDMO), and Kaida BioPharma ("Kaida" or the "Company"), an early-stage pharma company dedicated to advancing targeted anti-cancer therapies to address hormone-driven cancers affecting women, today announced they have entered into a manufacturing agreement for the production of Kaida's lead product candidate, KAD101.

  9. Applied StemCell Launches Two New Hypoimmunogenic hiPSC Products To Accelerate Allogeneic Cell Therapy Development 5/20/2025

    Applied StemCell, a CRO/CDMO that blends unique genome editing technology and iPSC expertise, announced the launch of their first hypoimmunogenic hiPSC products which are designed to empower researchers developing next-generation allogeneic cell therapies.

  10. Mirai Bio Announces Partnership With Thermo Fisher Scientific To Accelerate Development Of Genetic Medicines 5/20/2025

    Mirai Bio ("Mirai"), the industry's innovation partner for the co-creation of fully optimized genetic medicines, today announced a strategic collaboration with Thermo Fisher Scientific, the world leader in serving science, to benefit the life sciences and genetic medicines marketplace.